Related Experiment Video
Updated: Aug 7, 2026
06:38
Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria
Published on: February 28, 2025
Green tea flavonols inhibit glucosidase II
Alessandra Gamberucci1, Laura Konta, Angela Colucci
1Department of Physiopathology, Experimental Medicine and Public Health, University of Siena, and Unit for Development of Biomedical Research, Santa Maria alle Scotte Hospital, Siena, Italy.
Biochemical Pharmacology
|June 30, 2006
Summary
Green tea catechins inhibit glucosidase II, an enzyme crucial for glycoprotein processing. This finding suggests a potential mechanism for green tea
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Green tea catechins exhibit beneficial health effects, including antioxidant and anticancer properties.
- Polyphenolic compounds, like tea catechins, may exert antitumor effects by inhibiting glucosidase II.
- Glucosidase II plays a critical role in glycoprotein maturation and quality control within the endoplasmic reticulum.
Purpose of the Study:
- To investigate the inhibitory effect of tea catechins on glucosidase II activity.
- To determine the kinetic mechanism of inhibition by tea catechins.
- To compare the inhibitory potency of tea catechins with a known glucosidase inhibitor.
Main Methods:
- Enzyme inhibition assays were performed using rat liver microsomes as the enzyme source.
- 4-methylumbelliferyl glucoside and 4-nitrophenyl glucoside were utilized as substrates for glucosidase II.
- The effects of varying concentrations of tea catechins on enzyme activity were analyzed to determine IC50 and Ki values.
Main Results:
- Tea catechins demonstrated a concentration-dependent inhibition of glucosidase II activity.
- The inhibition kinetics were determined to be non-competitive.
- The IC50 and Ki values for specific tea catechins were found to be comparable to N-butyldeoxynojirimycin.
Conclusions:
- Tea catechins effectively inhibit glucosidase II activity in a non-competitive manner.
- The inhibitory potency of tea catechins is comparable to established glucosidase inhibitors.
- Interference with glycoprotein processing in the endoplasmic reticulum represents a potential mechanism for the health effects of tea catechins.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:24Phase II Reactions: Glucuronidation
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...